Clinical trial
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab &…
NCT00252564 · US Oncology Research, Industry · Completed
Key facts
| NCT number | NCT00252564 |
|---|---|
| Title | Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer |
| Official title | Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer |
| Lead sponsor | US Oncology Research, Industry |
| Collaborators | Bristol-Myers Squibb Industry Memorial Sloan Kettering Cancer Center Prologue Research International |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil, Cetuximab |
| Enrollment | 247 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2009 |
| First posted | Nov 11, 2005 |
| Last update posted | Feb 15, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: